JP2021534160A5 - - Google Patents

Info

Publication number
JP2021534160A5
JP2021534160A5 JP2021507740A JP2021507740A JP2021534160A5 JP 2021534160 A5 JP2021534160 A5 JP 2021534160A5 JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021534160 A5 JP2021534160 A5 JP 2021534160A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
riluzole
vas
reduces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046709 external-priority patent/WO2020037152A1/en
Publication of JP2021534160A publication Critical patent/JP2021534160A/ja
Publication of JP2021534160A5 publication Critical patent/JP2021534160A5/ja
Priority to JP2023179961A priority Critical patent/JP2024010017A/ja
Pending legal-status Critical Current

Links

JP2021507740A 2018-08-16 2019-08-15 疾患処置のためのリルゾール口腔内崩壊錠の使用 Pending JP2021534160A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023179961A JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
US62/764,864 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023179961A Division JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Publications (2)

Publication Number Publication Date
JP2021534160A JP2021534160A (ja) 2021-12-09
JP2021534160A5 true JP2021534160A5 (cg-RX-API-DMAC7.html) 2022-03-02

Family

ID=69525906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021507740A Pending JP2021534160A (ja) 2018-08-16 2019-08-15 疾患処置のためのリルゾール口腔内崩壊錠の使用
JP2023179961A Pending JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023179961A Pending JP2024010017A (ja) 2018-08-16 2023-10-19 疾患処置のためのリルゾール口腔内崩壊錠の使用

Country Status (14)

Country Link
US (1) US20210315865A1 (cg-RX-API-DMAC7.html)
EP (1) EP3836922B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021534160A (cg-RX-API-DMAC7.html)
KR (1) KR20210045423A (cg-RX-API-DMAC7.html)
CN (1) CN112584831A (cg-RX-API-DMAC7.html)
AU (1) AU2019322889A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002692A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190544A1 (cg-RX-API-DMAC7.html)
ES (1) ES2987802T3 (cg-RX-API-DMAC7.html)
IL (1) IL280657A (cg-RX-API-DMAC7.html)
MX (2) MX2021001563A (cg-RX-API-DMAC7.html)
PH (1) PH12021550218A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100880VA (cg-RX-API-DMAC7.html)
WO (1) WO2020037152A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
RS59490B1 (sr) * 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
MX2019009038A (es) * 2017-01-31 2019-12-09 L Manfredi Paolo D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
JP2022520061A5 (cg-RX-API-DMAC7.html)
JP2023002662A5 (cg-RX-API-DMAC7.html)
ES2295009T3 (es) Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
JP2022545005A5 (cg-RX-API-DMAC7.html)
JP2008501705A5 (cg-RX-API-DMAC7.html)
JP5911929B2 (ja) 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2018070614A5 (cg-RX-API-DMAC7.html)
JP2019515884A5 (cg-RX-API-DMAC7.html)
JP2021530543A5 (cg-RX-API-DMAC7.html)
JP2006503850A5 (cg-RX-API-DMAC7.html)
RU2018136580A (ru) Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты
JP2024520630A5 (cg-RX-API-DMAC7.html)
JP2015517523A5 (cg-RX-API-DMAC7.html)
JP2016516773A5 (cg-RX-API-DMAC7.html)
JP2023055858A (ja) 5′-アデノシン二リン酸リボース(adpr)の使用方法
JP2016537432A5 (cg-RX-API-DMAC7.html)
JP2022169780A5 (cg-RX-API-DMAC7.html)
JP2011502131A5 (cg-RX-API-DMAC7.html)
JP2023030113A5 (cg-RX-API-DMAC7.html)
JP2025118775A5 (cg-RX-API-DMAC7.html)
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP2023553253A5 (cg-RX-API-DMAC7.html)